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CD (3.3%, p< 0.001). 
Conclusion: Cl and HRR are independent and incremental predictors of cardiac death. 
Score incorporated age, symptoms, estrogen status, and 6 other coronary risk factors. 
Using previously defined thresholds, women were placed into low, intermediate, and high 
probability groups. Women were followed for 2.6 + 1.5 years for determination of prog- 
nostic outcomes. Outcomes considered were death (D), infarction (Ml), stroke (SK), 
other vascular (OV) and revascularization (REV). Results: Composite outcome results 
are shown in table below. Numbers in () are percentagesConclusion: In this cohort of 
women undergoing coronary angiography with a low prevalence of coronary disease, the 
Pretest Score stratified women significantly concerning both hard and soft prognostic 
outcomes. 
9:oo a.m. 
838-3 Fitness Versus Activity for Predicting Mortality in Men 
Amir Kavkha, Jonathan N. Myers, Sheela George, Joshua Abella, Takuya Yamazaki, 
Victor F. Froelicher, VA Palo Alto Health Care System, Palo Alto, CA 
Background: Both physical fitness and daily physical activity panerns are inversely 
associated with mortality, but a comparison between the two has not been performed in 
the same population. 
Methods: Physical fitness was determined as METS calculated from speed and grade 
for 642 males (age 59ul2) referred for treadmill testing for clinical reasons. Adulthood 
recreational activity pattern, expressed in kcallweek, was quantified using a modified 
Harvard Alumni Questionnaire at the time of exercise testing. Subjects were followed for 
a mean of 5.s2.0 Years with all-cause mortalitv as the endooint. 
Results: Recreational energy expenditure showed a graded pattern, with the more 
active demonstratina a lower morialitv ihazard ratio for 9000 kcal/week = 0.53. o=O.O3). 
1  ~  
I
However, adjusting for age, a Cox proportional hazards model showed that peak METS 
achieved was a stronger predictor of mortality than physical activity panern (hazard ratio 
for >5 METs=0.30, pcO.001). The Figure shows the reduction in risk for quartiles of fit- 
ness and activity we observed relative to the recent meta-analysis of Williams (Med Sci 
Sports Exert 2001; 33;754). Both fitness and activity levels in our subjects were similar 
to the meta-analysis in reducing risk. 
Conclusion: Both physical fitness and physical activity patterns were associated with 
survival, but fitness as estimated in METS from treadmill testing more powerfully predicts 
survival than activity from a questionnaire. 
9:15 a.m. 
838-4 Can a Pre-Exercise Test Score Predict Prognosis in 
Women With a Low Prevalence of Coronary Disease? 
The National Heart, Lung, and Blood institute- 
Sponsored Women’s ischemia Syndrome Evaluation 
(WISE) Study 
Anthonv Morise, Marian 8. Olson, C. Noel Bairey Merz, Sunil Mankad, William J. Rogers, 
Carl J. Pepine. Steven E. Reis, Barry L. Sharaf, George Sopko. Gerald M. Pohost. 
LeSlea J. Shaw, West Virginia University School of Medicine, Morgantown, WV 
Background: Recent guidelines for exercise testing suggest that a pretest score be 
used to stratify patients before exercise testing. A Pretest Score derived for use in 
women without known coronary disease has previously been shown to stratify women 
according to the prevalence of angiographic coronary disease. However, it has not been 
tested in a population with a low prevalence of coronary disease. Methods: To deter- 
mine whether this Pretest Score will stratify a separate cohon of women according to 
prognostic outcomes as well, we evaluated 563 women who underwent coronary angiog- 
raphy for suspected myocardial ischemia with an overall low (26%) prevalence of angio- 
graphic coronary disease, defined as xiO% stenosis in >l eoicardial vessel. The Pretest 
Prognostic Outcomes by Pretest Group 
Outcomes LOW Intermediate High p Value 
D, Ml 41164 (2.4) lo/245 (4.1) 121154 (7.6) 0.024 
D. MI, SK, OV 61164 (4.9) 21/245 (6.6) 22/154(14.3) 0.004 
D. MI. SK, OV, REV 15/164 (9.2) 40/245 (16.3) 46/154 (30) 0.001 
9:30 a.m. 
038-5 Should Age Be Part of the Duke Treadmill Score? 
Takuva Yamazaki Amir Kaykha. Jonathan Myers, Victor Froelicher, VA Palo Alto Health 
Care System, Palo Alto, CA 
Background: The Duke Treadmill Score is a validated means of estimating cardiovascu- 
lar (CV) mortality that has been recommended as part of the routine interpretation of 
treadmill tests. Age is a predictor of death but not included in the DTS. 
Methods: Analyses were performed on the first treadmill test perfoned on 6,352 con- 
secutive male veterans at the Palo Alto and Long Beach Veterans Affairs Medical Cen- 
ters since 1967. After removal of all CHF patients, 5,629 patients remained with a mean 
age of 59+11 years. The main outcome measure was CV mortality; during a mean follow- 
up of 6.6+4 years, there were 516 CV deaths. The DTS was calculated as METS - 
(4’[1 =angina occurred, P=reason for stopping])-(5’ amount abnormal ST depression). 
Results: Using Cox Hazard analysis, the DTS and age were found to have similar coeffi- 
cients but opposite sign, so a score was made as DTS-age. Using ROC analysis with CV 
mortality as the outcome, AUCs were calculated for the scores. DTS-age gave a signifi- 
cantly better discrimination than the DTS alone. 
Conclusion: The DTS minus age outperformed the DTS for predicting cardiovascular 
mortality. Afler validation in other populations, age should be subtracted from the DTS 
calculation as part of treadmill test interpretation. 
9:45 a.m. 
838-6 Association of Abnormal Heart Rate Recovery and 
Chronotroplc incompetence With Obesity in a Healthy 
Cohort 
Michael S. Lauer, David Yu. Claire E. Pothier, Eugene H. Blackstone, Cleveland Clinic 
Foundation, Cleveland, OH 
Background: Obesity is known to be associated with abnormalities of autonomic ner- 
vous system balance. We hypothesized that obesity is also associated with exercise 
hearl rate abnormalities, which are reflective of autonomic tone. 
Methods: We studied 3,071 adults (mean age 49; 65% men) without a history of cardiac 
disease or use of cardiovascular medications who referred for symptom-limited exercise 
stress testing. Exact height and weight were directly measured per routine protocol. Sub- 
jects were divided into sex-specific quintiles of body mass index (BMI) (quintile 5 > 30 kg/ 
n? in men, > 26 kg/m’ in women). An abnormal heart rate recovery (HRR) was defined 
as ( 12 beats per mswte during the first minute after exercise. Chronotropic incompe- 
tence (CRI) was defined as failure to use 60% of heart rate resewe. 
Results:There were 333 subjects (11%) who had an abnormal HRR, 222 (7%) who had 
CRI, and 169 (6%) who had impaired functional capacity for age and gender. Abnormali- 
ties of all 3 variables were particularly marked in the highest quintile of BMt (Figure). 
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After adjusting for age, gender, blood pressure, smoking status, us& of aspirin and/or 
lipid lowering medication, resting heart rate, and exercise capacity in sequential boot- 
strapping logistic analyses, obesity (i.e.. BMI quintile 5) was independently associated 
wth an abnormal HRR (adjusted odds ratio [OR] 1.66 (1.26 - 2.34) and with CRI 
(adjusted OR 2.23 (1.56 - 3.17). 
Conclusion: Obesity is independently associated with abnormal HRR and with CRI. 
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1158-68 Chronic Subcutaneous Administration of the Cardiac 
Peptide BNP in Experimental Heart Failure Does Not 
Result in the Development of Tolerance to Exogenous 
BNP 
Homa H. Chen John A. Schirger, Alessandro Cataliotti, Gail Hady, John C. Burnett, Jr., 
Mayo Clinic and Foundation, Rochester, MN 
BACKGROUND: Brain natriuretic peptide (BNP) is a cardiac peptide with vasodilating. 
lusitropic, natriuretic and renin-angiotensin-aldosterone (RAAS) inhibiting properties 
which are mediated by the second messenger cGMP. BNP is FDA approved for the man- 
agement acute congestive heart failure (CHF). We have previously shown that chronic 
subcutaneous (SQ) administration of BNP in experimental CHF improves hemodynam- 
its, however, it is unknown if chrome BNP administration leads to the development of tol- 
erance to exogenous BNP. METHODS: We compared the cardiorenal effects of acute 
administration of SQ BNP (*g/Kg) in a group of dogs (n=5) with pacing induced CHF 
(180 bpm for 10 days) to a separate group of CHF dogs (n=6), who received chronic SQ 
BNP @g/Kg) three times a day during10 days of pacing. RESULTS: Chronic SQ BNP 
therapy for 10 days improved cardiac output (3.6r 0.4 vs 2.5* 0.1 Umin) with decreased 
pulmonary capillary wedge pressure (PCWP) (9+ 2 vs 16* 3 mmtig) and systemic vas- 
cular resistance (35* 5 vs 45+ 4 RU) as compared to the untreated group (~~0.05). 
Importantly, acute admlnistration of SQ BNP on day 11, resulted in similar increases in 
plasma cGMP (35+ 5 vs 29* 2 pmolfml) and urinary cGMP excretion (UcGMPV) (6000+ 
1000 vs 4OOOi 600 pmollmin) in both the chronic SQ BNP treated and the untreated 
groups (p>O.O5). These were associated with decreased cardiac filling pressures and 
increased in urine flow, which were also similar in both the chronic SO BNP treated and 
the untreated groups (p>O.O5). CONCLUSION: In this model of experimental CHF, 
chrome SQ BNP administration did not result in the development of tolerance es demon- 
strated by similar increases in plasma cGMP and UcGMPV in the chronic BNP treated 
and the untreated groups with acute administration of SQ BNP. Fwthermore, acute 
administration of SQ BNP resulted in similar decreases in cardiac filling pressures and 
increases in urine flow. This may have important clinical implications, suggesting that 
chronic SQ BNP administration does not lead to the development of tolerance to acute 
BNP administration and suppolting this strategy as efficacious for chronic protein-based 
therapy for CHF. 
1158-69 Chronic Oral Endothelin-A Receptor Antagonism 
Activates the Renin-Angiotensin-System With 
Persisting Sodium Retention in Experimental Heart 
Failure 
John A. Schiraer, Homg H. Chew John C. Burnett, Jr., Mayo Cknic and Foundation, 
Rochester, MN 
Background: Although acute endothelin (ET) receptor antagonism improves systemic 
hemodynamics in congestive hearl failure (CHF). clinical trials with chronic ET receptor 
antagonism reporl exacerbation of CHF symptoms. The mechanisms for this remain 
unclear. Methods: We first defined the temporal activation of the ET and renin-angio- 
tensin-systems (RAS) at the onset of sodium retention I” a canine model of pacing 
induced CHF. Next, we evaluated the effect of chronic oral ET-A receptor antagonism 
(LU135252: started day 3 of pacing) on sodium excretion, glomerular filtration rate and 
neurohumoral activity in canine CHF. Results: Plasma endothelin-1 but not plasma renin 
activity (PRA) increased with the onset of sodium retention in CHF (n=5) compared to 
normal dogs (n=5) (17.Oi2.0 vs 7.0+_ 2.0 pg/mL, ~~0.05). Northern blot analysis demon- 
strated myocardial endothelin-I mRNA activation at the onset of sodium retention (n=5) 
compared to normal dogs (n=5). Myccardial angiotensin II was not activated at this point 
in either group. After 7 days of treatment (n=7) with LU135252 there was no difference in 
sodium retention (73 vs 422 uEqlmin) or glomerular filtration rate vs. untreated CHF 
dogs (n=6). PRA (7~2 vs 1624 nglmlihr, ~~0.05) and plasma endothelin-1 increased 
with treatment. After 16 days of treatment (n=9), despite maintaining glomerular filtration 
rate at normal values, LU135252 did not increase sodium excretion vs. untreated CHF 
dogs (n=E), and PRA tended to further increase with treatment. Conclusion: Activation 
of the ET system precedes activation of the RAS in CHF. ET-A receptor antagonism in 
CHF does not increase sodium excretion but may further activate the RAS. These find- 
ings suggest a mechanism for the exacerbation of CHF symptoms observed in clinical tri- 
als with chronic ET receptor antagonism and support a possible strategy for combining 
antagonism of the ET system and RAS in CHF. 
1158-70 Role of Kinins and Angiotensin II Type 2 Receptors in 
the Cardioprotective Effect of Angiotensin II Type 1 
Receptor Antagonists in Brown Norway Kininogen- 
Deficient Rats 
Yun-He Liu, Xiao-Ping Yang, Ai-Li Yu. Edward G. Shesely, Oscar A. Carretero. Henry 
Ford Hospital, Detroit, Ml 
Background: Previously we reported that lack of kinins influence neither cardiac function 
nor development of HF post-MI; however, klnins play an important role in the cardiopro- 
tective effect of ACEi. Here, we studied the role of kinins and AT, receptors in the protec- 
tive effect of AT,-ant in rats with HF. 
Methods Brown Norway Katholiek (BNK) rats, which are genetically deficient in kinins 
due to a mutation in the klninogen gene, and their wild-type control (BN) underwent 
either sham or coronary artery ligation. 2 months later, they were treated for 2 months 
with a) vehicle, b) AT,-ant (L158609, 1.5 mglkgiday), c) AT,-ant + AT,-ant (PD-123319, 
10 mgikglday), or d) AT,-ant + kinin B, receptor antagonist (icatibant, 100 @@day, in 
BN). We measured left ventricular end-diastolic volume (LVEDV), end-systolic volume 
(ESV) and ejection fraction (EF) by ventnculography, and (interstitial collagen fraction- 
ICF), myocyte cross-sectional area (MCSA ). assessed histologically and heart weight 
(HW). 
Results In BNK, the protective effect of AT, -ant was dimlnished, blockade of AT, recep- 
tors did not influence the effect of AT, -ant on cardiac function and fibrosis; however, it 
blocked the effect of AT,-ant on hypertrophy. and I” BN rats, effect of AT,-ant was 
blocked by ATP-ant. and partially blocked by icatibant. 
Conclusion: 1) AT, receptors acting via kinins play an important role in the cardioprotec- 
tive effect of AT,-ant. 2) the antihypertrophic effect of AT,-ant is mediated by a factor 
other than kinins. 
Effect of AT&ant on cardiac function and remodeling in BN and BNK 
BN BNK 
Sha HF- HF- HF.AT1 ant 
m Vehicle ATlan + AT2ant 
LVEF(%) 64* 25 f 42 f 
1 3(l) 2(2) 
LVEDV 356 646* 562* 
(PI) +29 64(l) 28(2) 
HW (m9/ 254 324+ 264* 
1OOgBW) + 7 12(l) 6(2) 
ICF (%) 4.9 * 10.4 * 6.1 * 
0.3 0.5(l) 0.7(2) 







Sha HF- HF- HF.ATlant 
m Vehicl ATla cATPant 
e nt 
68* 26* 3322 34+3 
1 l(4) 
417 669 * 743 * 761 *52 
*20 49(4) 37 
261 306 * 263 * 323+ 17(6) 
* 7 lO(4) 7(5) 
4.9+ 12.4* ll+ 10 * 0.9 
0.1 l(4) 0.9 
Mean SE; (1) : p < 0.01 versus BN-sham; (2): p < 0.01 versus BN-HF-Vehicle; (3): p 
< 0.001 versus BN-HF.ATl-ant; (4): p < 0.001 versus BNK-sham; (5): p =Z 0.05 
versus BNK-HF-ATl-ant; (6): p < 0.05 versus BNK-HF-ATl-ant. 
